To study the effect of a new drug in treatment of complicated urinary tract infections.
Phase 3
Not yet recruiting
- Conditions
- Health Condition 1: N390- Urinary tract infection, site notspecified
- Registration Number
- CTRI/2022/11/047325
- Lead Sponsor
- cipla pharmaceuticals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
COMPLICATED UTI
URINE CULTURE GROWING MBL PRODUCING GNB
Exclusion Criteria
MORIBUND PATIENTS
MIXED GROWTH IN CULTURE
ALLERGY TO MEDICATIONS
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CLINICAL AND MICROBIOLOGICAL CLEARANCE OF BACTERIA FROM URINE.Timepoint: AFTER 14 DAYS OF TREATMENT
- Secondary Outcome Measures
Name Time Method TO SEE RELAPSE OF BACTERIAL INFECTIONS IN COMPLICATED URINARY TRACT INFECTION CASESTimepoint: WITHIN 28 DAYS OF TREATMENT